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In the early 1980’s it was demonstrated that density gradi-
ent isolation of peripheral blood mononuclear cells led to
an unpredictable loss of lymphocyte populations and
unacceptable levels of error for even routine CD4+ and
CD8+ T cell enumeration. The error associated with this
manipulation was further amplified by errors associated
with cryopreservation. Based on these results, clinical flow
cytometry laboratories have uniformly adopted whole
blood lysis techniques for enumeration of leukocytes in
peripheral blood. We have developed an extended menu
of standardized immunophenotyping assays performed
using anticoagulated whole blood. Based on the recom-
mendations of the Human Immunology Project, the assays
offer results that can be correlated with other clinical sites
where these recommendations are followed, while offering
flexibility for characterization of additional antigens and
cell populations. The “Core” assays are cocktails of 8-10
antibodies that identify the cell populations of interest.
To each core, an unlimited number of additional antigens
of interest can be quantified. This is accomplished by
replicating the core cocktail as needed. Added to this core
cocktail are antibodies for detection of inducible antigens.
These inducible antigens are detected using fluorochromes
and detectors optimized for sensitivity and reproducibility.
Included with each assay is a process control. This control
uses a stabilized whole blood preparation that allows the
entire staining procedure to be evaluated, from pipetting
of the blood through RBC lysis and analysis. Target values
are determined internally for each lot of control material
and each run is verified to fall within the acceptable range
for each parameter. The laboratory also performs a stan-
dardization calibration protocol to adjust photomultiplier
tube voltages based on a fluorescent calibration bead. This
calibration allows for quantitative fluorescence (Median
Fluorescence Intensity, or MFI) to be compared over the
duration of a study. Through the use of process controls,
instrument standardization, and reagent validation,
day-to-day and user-to-user variability is minimized. This
approach allows for the complexity of clinical research
while minimizing the error typically associated with such
assays in the research setting. Adoption of similar prac-
tices can improve data quality and thus, the opportunity
to identify changes in peripheral immune composition
related to disease state and treatment.
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